Q3week Carboplatin With Weekly Abraxane And Avastin + Subsequent Dose-Dense Ac With Avastin As Neoadjuvant Therapy In Resectable And Unresectable (Stage Iia-Iiib) Her2-Negative Breast Cancer

Trial Profile

Q3week Carboplatin With Weekly Abraxane And Avastin + Subsequent Dose-Dense Ac With Avastin As Neoadjuvant Therapy In Resectable And Unresectable (Stage Iia-Iiib) Her2-Negative Breast Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Cyclophosphamide (Primary) ; Paclitaxel (Primary) ; Carboplatin; Doxorubicin
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Jun 2017 Results assessing mitochondrial gene fusions in breast cancer by RNA sequencing of pre and post treatment breast cancer samples obtained from neoadjuvant clinical trials BrUOG 211A/211B, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 22 Apr 2013 Planned end date changed from 1 Jun 2013 to 1 Dec 2016 as reported by ClinicalTrials.gov.
    • 01 Feb 2012 Planned End Date changed from 1 Jun 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top